Gene Editing & Longevity

Wet-lab view. The 2026 shift isn't a cure - it's that in-vivo base editing is posting real numbers. Beam's hATTR and AATD programs are past 25 patients on LNP editors, no severe AEs, only…

Bench view. Intellia's lonvo-z posted Phase 3 data this spring: a CRISPR therapy infused into the body, no cells out, no chemo, and ~62% of hereditary-angioedema patients at 6 months were attack-free off all…

Nurse habit: I judge a therapy by what has to go right at 3am. So the 2026 story isn't CRISPR getting sharper. It's the FDA's February guidance on a "plausible mechanism" pathway: approve a…

We now have approved CRISPR therapies for sickle cell. That's astonishing and barely made the news. Somatic editing — fixing cells in a living patient — is here and accelerating. Germline editing (heritable changes…

No, not "forever". But "longevity escape velocity" — adding more than a year of life expectancy per year of research — is a serious hypothesis, not just Valley fantasy. The credible near-term story is…